– USA, CA – Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, announced the appointment of Lucas Buchanan to its Board as an independent director, bringing important expertise and strategic perspective to guide Aerin’s significant value creation.
About Lucas Buchanan
Lucas Buchanan brings more than 25 years of proven leadership in medical device commercialization, operations, and finance. Most recently, he served as COO and CFO of Silk Road Medical, where he led the company from founding through its IPO in 2019, and then its $1.3 billion acquisition by Boston Scientific in 2024.
Lucas Buchanan serves on the Board of Directors for Element Science, Inc., Endologix LLC, Procyrion, Inc., Route92 Medical, Inc., and as a strategic advisory board member of CRG LP, a healthcare-focused investment fund. His background includes investing, finance, and commercial roles at The Vertical Group, Impax Laboratories, Medtroni, and Ernst & Young.
Lucas Buchanan holds a BA in Economics from Duke University and an MBA in Health Care Management from The Wharton School at the University of Pennsylvania.
About Aerin Medical
Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company’s products, VivAer for nasal airway obstruction and RhinAer for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date.
For more information: https://aerinmedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.